anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital）

N/A

Report date: 2022/07/13 15:30:39

Base Information

Drug Nameanti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsTumor necrosis factor ligand superfamily member 13 inhibitors
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts General Hospital
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A